[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100296873":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":43,"locations":49,"responsibleParty":184,"collaborators":186,"id":196,"slug":197,"hasResults":198,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":204,"sex":205,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":10,"studyType":211,"phases":10,"briefSummary":212,"conditions":213,"keywords":10,"overallStatus":87,"whyStopped":10,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},{"fullName":5,"class":6},"International Agency for Research on Cancer","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cases",null,"Incident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in five Latin American cities (Barretos, Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes",[13],"Other: lifestyle",{"label":15,"type":10,"description":16,"interventionNames":17},"Controls","Women with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+\u002F- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"lifestyle","Observational study",[9,15],[24,28,31,34,37,40],{"name":25,"affiliation":26,"role":27},"Sabina Rinaldi, PhD","International Agency for Research on Cancer, Lyon, France","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":30,"role":27},"Maria Luisa Garmendia, PhD","INTA, Universidad de Chile, Santiago, Chile",{"name":32,"affiliation":33,"role":27},"Carolina Porras, PhD","Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Costa Rica",{"name":35,"affiliation":36,"role":27},"Gabriela Torres-Mejía, PhD","Instituto Nacional de Salud Pública, Cuernavaca, Mexico",{"name":38,"affiliation":39,"role":27},"Gloria I Sánchez, PhD","Grupo Infección y Cáncer, Universidad de Antioquía, Medellín, Colombia",{"name":41,"affiliation":42,"role":27},"Fabiana Vazquez","Barretos Cancer Hospital",[44],{"name":25,"role":45,"phone":46,"phoneExt":47,"email":48},"CONTACT","+33 472738485","8328","rinaldis@iarc.who.int",[50,61,73,79,85,107,118,126,134,142,150,161,172],{"facility":42,"status":51,"city":52,"state":10,"zip":10,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":10},"COMPLETED","Barretos","Brazil","BR",{"type":56,"coordinates":57},"Point",[58,59],-48.56778,-20.55722,{"lat":59,"lon":58},{"facility":62,"status":63,"city":64,"state":65,"zip":10,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":10},"INC","ACTIVE_NOT_RECRUITING","Santiago","Independencia","Chile","CL",{"type":56,"coordinates":69},[70,71],-70.64827,-33.45694,{"lat":71,"lon":70},{"facility":74,"status":63,"city":64,"state":75,"zip":10,"country":66,"countryCode":67,"cosmosGeoPoint":76,"geoPoint":78,"contacts":10},"Hso-Crsco","Peñalolén",{"type":56,"coordinates":77},[70,71],{"lat":71,"lon":70},{"facility":80,"status":63,"city":64,"state":81,"zip":10,"country":66,"countryCode":67,"cosmosGeoPoint":82,"geoPoint":84,"contacts":10},"FALP","Providencia",{"type":56,"coordinates":83},[70,71],{"lat":71,"lon":70},{"facility":86,"status":87,"city":88,"state":89,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Grupo Infección y Cáncer. Universidad de Antioquia","RECRUITING","Medellín","Antioquia","050010","Colombia","CO",{"type":56,"coordinates":94},[95,96],-75.57151,6.245,{"lat":96,"lon":95},[99,103],{"name":100,"role":45,"phone":101,"phoneExt":10,"email":102},"Gloria Sanchez, MSc, PhD","+57 3014201831","gloria.sanchez@udea.edu.co",{"name":104,"role":45,"phone":105,"phoneExt":10,"email":106},"Maria Agudelo, MD","+57 3012974825","ceci886@hotmail.com",{"facility":108,"status":87,"city":109,"state":109,"zip":10,"country":91,"countryCode":92,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"International Hospital of Colombia","Bucaramanga",{"type":56,"coordinates":111},[112,113],-73.11895,7.125,{"lat":113,"lon":112},[116],{"name":117,"role":45,"phone":10,"phoneExt":10,"email":10},"Ana I Orduz",{"facility":119,"status":51,"city":120,"state":10,"zip":10,"country":91,"countryCode":92,"cosmosGeoPoint":121,"geoPoint":125,"contacts":10},"Facultad de Medicina, Universidad del Norte","Barranquilla",{"type":56,"coordinates":122},[123,124],-74.78132,10.96854,{"lat":124,"lon":123},{"facility":127,"status":87,"city":109,"state":10,"zip":10,"country":91,"countryCode":92,"cosmosGeoPoint":128,"geoPoint":130,"contacts":131},"Hospital Internacional de Colombia Fundacion Cardiovascular de Colombia",{"type":56,"coordinates":129},[112,113],{"lat":113,"lon":112},[132],{"name":133,"role":45,"phone":10,"phoneExt":10,"email":10},"Norma C Serrano",{"facility":135,"status":87,"city":109,"state":10,"zip":10,"country":91,"countryCode":92,"cosmosGeoPoint":136,"geoPoint":138,"contacts":139},"SENOSAMA foundation",{"type":56,"coordinates":137},[112,113],{"lat":113,"lon":112},[140],{"name":141,"role":45,"phone":10,"phoneExt":10,"email":10},"Claudia Amaya",{"facility":143,"status":51,"city":144,"state":10,"zip":10,"country":91,"countryCode":92,"cosmosGeoPoint":145,"geoPoint":149,"contacts":10},"Instituto de Oncología HematoOncologos","Cali",{"type":56,"coordinates":146},[147,148],-76.5199,3.43054,{"lat":148,"lon":147},{"facility":151,"status":87,"city":152,"state":10,"zip":10,"country":91,"countryCode":92,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Public Health University of Narino","Pasto",{"type":56,"coordinates":154},[155,156],-77.27846,1.21456,{"lat":156,"lon":155},[159],{"name":160,"role":45,"phone":10,"phoneExt":10,"email":10},"Alvaro Paz",{"facility":162,"status":51,"city":163,"state":164,"zip":10,"country":165,"countryCode":166,"cosmosGeoPoint":167,"geoPoint":171,"contacts":10},"Agencia Costarricense de Investigaciones Biomédicas (ACIB)","San José","Provincia de San José","Costa Rica","CR",{"type":56,"coordinates":168},[169,170],-84.08489,9.93388,{"lat":170,"lon":169},{"facility":173,"status":51,"city":174,"state":175,"zip":176,"country":177,"countryCode":178,"cosmosGeoPoint":179,"geoPoint":183,"contacts":10},"Instituto Nacional de Salud Pública (INSP)","Cuernavaca","Morelos","69100","Mexico","MX",{"type":56,"coordinates":180},[181,182],-99.23075,18.9261,{"lat":182,"lon":181},{"type":185,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[187,189,191,193,195],{"name":188,"class":6},"University of Chile",{"name":190,"class":6},"Fundación Inciensa",{"name":192,"class":6},"Instituto Nacional de Salud Publica, Mexico",{"name":194,"class":6},"Universidad de Antioquia",{"name":42,"class":6},"100296873","precama-molecular-subtypes-of-premenopausal-breast-cancer-in-latin-american-women-100296873",false,"NCT03144648","PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women","Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a Multicenter Population-based Case-control Study","PRECAMA","Inclusion Criteria:\n\n* woman between 20 and 45 years old\n* woman less than 3 years older or younger than the case\n* living in the area that the study is taking place during the past 3 years\n* woman menstruated at least once in the past 12 months\n* woman diagnosed with a primary breast cancer by histopathological examination (only for cases)\n\nExclusion Criteria:\n\n* woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens (for example, tamoxifen) (except treatment for non-melanoma skin cancers)\n* woman taking (or has previously taken) any of the following medications in the past 6 months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane), Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol)\n* woman suffering from chronic kidney failure\n* woman having a pathology that will hinder adequate communication\n* woman who is pregnant or nursing\n* woman who has been previously diagnosed with a cancer(except for non-melanoma skin cancers)\n* any other reason to exclude",true,"FEMALE","20 Years","45 Years",{"count":209,"type":210},3000,"ESTIMATED","OBSERVATIONAL","Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival.\n\nTo improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study).\n\nPRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following:\n\n1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols\n2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes\n3. To improve the identification of specific endogenous\u002Fexogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes.\n4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer.\n\nThe results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.",[214],"Breast Cancer Female","2025-05-01",{"date":217,"type":218},"2025-05-06","ACTUAL",{"date":220,"type":218},"2012-10-12",{"date":222,"type":210},"2025-12-30",{"name":5,"class":6},13]